ReviewAngewandte Chemie (International ed. in English)2026
Using Synthetic Glycans to Investigate Anti-Glycan Antibodies and Explore Their Medical Potential.
Review in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The dynamic glycan layer that surrounds human and microbial cells plays an essential role in the immune system's capacity to maintain immune tolerance and equilibrium, fight pathogens and cancer. Endogenous anti-glycan antibodies are an indispensable part of immune surveillance, identifying abnormal microbial glycans, viral glycoproteins, and altered tumor-associated carbohydrate antigens. These glycans serve in turn as attractive targets for passive and active immunization strategies in a range of human diseases. The enormous complexity and structural diversity of glycans has made it very difficult to unlock their full biomedical potential. Recent advances in glycan synthesis, including automated solid-phase assembly, chemoenzymatic strategies, and one-pot approaches, enabled unprecedented access to well-defined, homogenous structures. Hence, synthetic glycans of increasing structural complexity pave the way for a range of applications, from profiling endogenous antibody repertoires for biomarker discovery to therapeutic antibody development and vaccine design. Here, we summarize the strategies to utilize synthetic glycans for antibody development and their application in basic research and translational medicine. We outline how anti-glycan antibodies are utilized for diagnostic and therapeutic purposes, while emphasizing the power of synthetic glycans and highlighting their potential in personalized medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.